1131TiPPHASE 1 STUDY EVALUATING SAFETY AND TOLERABILITY OF MEDI4736, AN ANTI-PROGRAMMED CELL DEATH LIGAND-1 (PD-L1) ANTIBODY, IN COMBINATION WITH DABRAFENIB AND TRAMETINIB OR TRAMETINIB ALONE IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA

Abstract Background: Targeted treatments have significantly improved outcomes in patients (pts) with metastatic melanoma (MM). The combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, provides high response rates in BRAF mutation-positive melanoma (BRAF V600E/K melanoma). Tr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2014-09, Vol.25 (suppl_4), p.iv392-iv393
Hauptverfasser:	Gordon, M.S., Lutzky, J., Lawrence, D., Butler, M., Ascierto, P.A., Hug, B., Blake-Haskins, A., Di Pietro, A., Li, X., Robbins, P.B., Ribas, A.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!